> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 1st Year Generic Drug Cluster Accomplishments
- URL: https://www.fdaweb.com/1st-year-generic-drug-cluster-accomplishments/
- Published: 2022-07-28T12:00:00.000Z
- Updated: 2026-09-14T17:53:48.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5152396

FDA is listing the accomplishments from the first year’s work of the Generic Drug Cluster, a multi-country forum working toward a common understanding of each member agency’s generic drug regulatory requirements and toward increased scientific alignment. An online [report](https://www.fda.gov/drugs/generic-drugs/generic-drug-cluster-one-year-progress-report?ref=fdaweb.com) says the cluster meetings “enabled an agreement for gathering and assessing data from participating agencies concerning an oncology treatment. The assessment by the agencies of that combined data may lead to a faster approval pathway for that type of drug or drug class in a critically needed cancer treatment.”

The group also agreed on data gathering and combining to assess the bioequivalence of a mental health treatment, again with the possibility of leading to a faster approval pathway for this class of drugs.

Cluster participants agreed to share data on human testing of certain drugs in which there are discrepancies in the testing populations. And they are establishing a process for sharing data integrity concerns on bioequivalence and pharmacokinetic data in generic drug applications.

The report concludes that information exchange and discussion at the cluster meetings support FDA efforts to reach scientific consensus on approval standards for various drug products, including complex drug products. It says such discussions can be the basis for future International Council for Harmonization guidelines used for the development of complex drug products.

“It is the goal of this cluster to collaborate early in the regulatory process so that agencies participating in the cluster can facilitate the development and approval of various generic products in a more efficient way with similar standards,” FDA says. “This will ultimately enable patients around the world to access high-quality generic drug products in a cost-effective manner.”